Abstract: A microbial oil comprising: a specific amount of at least one polyunsaturated fatty acid having at least 20 carbon atoms in fatty acid alkyl ester form and/or in free fatty acid form; and specific amount of thermally-produced fatty acid having from 16 to 22 carbon atoms in a fatty acid alkyl ester form and/or a free fatty acid form. A production method thereof comprising: providing a starting oil containing at least one polyunsaturated fatty acid having at least 20 carbon atoms in an alkyl ester form and/or a free fatty acid form obtained from microbial biomass; performing a rectification of the starting oil under specific conditions; and obtaining the aforementioned microbial oil. A concentrated microbial oil obtained using the production method described above, and a production method thereof. An agent for treating or preventing an inflammatory disease comprising the microbial oil or the concentrated microbial oil.

Abstract: Disclosed herein are compositions and methods for modulating a macrolide antimicrobial, modulating an immune function, increasing the effectiveness of an antibiotic, and/or increasing the number and effectiveness of alveolar macrophages in treating a vertebrate animal. The method comprises feeding to the animal a feed composition comprising (1, 3), (1, 6), beta-glucans and optionally mannans to increase the number of alveolar macrophage cells, and administering a macrolide antibiotic to the animal.

Abstract: The present invention relates to a new plant growth regulation composition comprising a compound of Formula (Ia) and trinexapac-ethyl. (Ia). It also relates to a method for enhancing or regulating the growth of plants comprising applying said composition.

Abstract: The use of long-chain alkenones to impart desired characteristics in personal care compositions for topical applications is described. The preparation of mixtures long-chain alkenones and synthetic derivatives thereof is presented. Examples of compositions include abrasive soaps, with alkenones serving as natural exfoliating agents. Alkenones and their derivatives can serve as emollients, occlusive agents, encapsulating agents, stabilizing agents, binding agents, thickening agents, surfactants, and antimicrobials.

Abstract: A non-injectable formulation or formulation for instillation, including self-assembling hydrogels formed of gelators such as the Food and Drug Administration's Generally Regarded as Safe (GRAS) compounds like ascorbyl palmitate, in the form of capsules, tablets, oral suspensions, enemas, and rectal or vaginal suppositories or inserts have been developed. In a preferred embodiment, the formulation contains anti-inflammatories, anti-infectives, or other therapeutic, prophylactic, or diagnostic agents that can be administered orally, especially when lower blood levels relative to tissue levels of agent are preferred. In the most preferred formulation, the composition contains tacrolimus-loaded ascorbyl palmitate gel microfibers containing nanostructures (“hydrogels”).

Abstract: The present invention relates to a composition, especially a photoprotective cosmetic composition, comprising at least: photonic particles having a mean size of from 0.5 ?m to 100 ?m, each including an ordered periodic arrangement of monodisperse nanoparticles or of empty spaces, leading to attenuation of the radiation in the wavelength range extending from 250 nm to 1800 nm, preferably from 250 nm to 400 nm, b) at least one UV-screening agent, and at least one particular acrylic polymer.

Abstract: Disclosed herein are spatial insect repellent compositions comprising pyrethrins and about 5% to about 20% by weight p-menthane-3,8-diol.

Abstract: Provided are nanoparticles for the selective death of cancer cells through ferroptosis and a method of preparing the same. More particularly, the nanoparticles are in a form in which a cancer cell-targeting hydrogel and iron particles are bound and aggregated, and are selectively accumulated in cancer cells, and thus exhibit an effective cancer cell killing effect through ferroptosis, and accordingly, are expected to exhibit high therapeutic effects due to less side effects.

Abstract: The present invention relates to combinations of a diamide insecticidal compound selected from broflanilide, chlorantraniliprole, cyantraniliprole, cyclaniliprole, cyhalodiamide, flubendiamide or tetraniliprole in combination with at least one multi-site fungicidally active compound and at least another insecticidal compound. The said combinations demonstrate excellent efficacy in the control of unwanted pests.

Abstract: The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

Abstract: The invention relates to a pharmaceutical formulation, e.g. a paediatric formulation, of odevixibat, which comprises a plurality of small particles. The formulation may be used in the treatment of liver diseases such as bile acid-dependent liver diseases, and particularly cholestatic liver diseases such as biliary atresia, progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS) and paediatric cholestatic pruritus. The invention also relates to a process for the preparation of the pharmaceutical formulation.

Abstract: Therapeutically-active compositions that combine strontium with at least one additional molecules that increase the overall therapeutic potency of the combination beyond the potency of any of the separate constituents. Specifically, the combinations perform two important functions; (1) they increase the ability of topically-applied strontium to inhibit both acute sensory irritation (e.g., pruritus and pain), redness, swelling and inflammation (collectively defined for purposes of this description, “irritation”) and the chronic irritation that is characteristic of and contributes to the development and maintenance of painful or pruritic neuropathic conditions; and (2) they decrease the strontium activated pathways that are known to enhance the development and maintenance of pain, pruritis and neuropathic conditions.

Abstract: Compositions and methods for enhancing antigen-specific immunity in a subject are provided. Pharmaceutical compositions including an effective amount of an immuno-stimulatory cardiolipin as an adjuvant in combination with an antigen and methods of use thereof for stimulating protective immunity to the antigen in a subject are provided. Administration of the combination of the antigen and cardiolipin adjuvant is effective to enhance antigen-specific immunity in a subject to a greater degree than administering to the subject the same amount of the antigen alone. The active agents can be administered together or separately. In preferred forms the cardiolipin is cardiolipin species (C18:2)4. In preferred forms the antigen is formulated as a vaccine, such as an influenza vaccine. A preferred amount by weight of each reagent is about 10-40% cardiolipin to about 90-60% antigen(s), inclusive.

Abstract: The present invention relates to a composition for a keratin substance, such as skin, comprising: (a) at least one plate type filler having a particle size of 10 ?m or less, preferably 5 ?m or less, and more preferably 3 ?m or less; (b) at least one pearlescent pigment having a particle size of 15 ?m or less, preferably 12 ?m or less, and more preferably 10 ?m or less; and (c) at least one hollow or porous particle, wherein the (a) plate type filler has a refractive index of 2.0 or less, preferably 1.9 or less, and more preferably 1.8 or less, and the (b) pearlescent pigment has a colored reflection. The composition according to the present invention can provide a keratin substance with sufficient coverage of imperfections on the keratin substance, while providing the keratin substance with brightness and natural finish.

Abstract: The present invention relates to an anti-inflammatory composition comprising a graphene nano-structure as an active ingredient. Specifically, the present invention relates to a pharmaceutical composition for preventing or treating an inflammatory disease, and a cosmetic composition or feed composition for preventing or improving an inflammatory disease, which include the anti-inflammatory composition, and a method of treating an inflammatory disease, including administering the composition to a subject in need thereof.

Abstract: The present invention relates to a hair colouring and/or bleaching composition comprising at least a first aqueous component (i) and a second aqueous component (ii) being mixed prior to application onto hair, wherein the first aqueous component (i) comprises, in a cosmetically acceptable carrier one or more oxidizing agent(s), and the second aqueous component (ii) comprises, in a cosmetically acceptable carrier, one or more alkalizing agent(s) selected from the group consisting of ammonia, its salts and mixtures thereof wherein the first component (i) or the second component (ii) or both comprise at least a first and a second malodor suppressant and optionally one or more further malodor suppressants, or the first component (i) comprises at least a first malodor suppressant and the second component (ii) comprises at least a second malodor suppressant, the first and the second malodor suppressant and any further malodor suppressant forming a malodor suppressant system in the hair colouring and/or bleaching com

Abstract: The present disclosure relates to the field of delivery systems. Described herein is a powdered composition comprising including granules having a hydrophobic active ingredient dispersed in a polymeric matrix, wherein the powdered composition contains a fireproofing agent. The fireproofing agent defined in the present disclosures includes talc that, when present in the powdered composition, prevents a dust explosion risk when the powdered composition is manufactured, handled or dosed into a consumer product.

Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.

Abstract: The present disclosure relates to use of Rivastigmine in the preparation of an anti-radiation medicament, and belongs to the field of medical technology. The present disclosure provides use of Rivastigmine in the preparation of an anti-radiation medicament. Researches show that Rivastigmine significantly promoted the proliferation of Lgr5+ stem cells receiving 10 Gy radiation (after being irradiated with 10 Gy radiation for 10 d, Lgr5+ stem cells cultured in a Rivastigmine-containing culture solution had an increment 14.2 times of that of the Lgr5+ stem cells cultured in a Rivastigmine-free culture solution). Rivastigmine also significantly reduced the mortality of mice after being irradiated with 10 Gy radiation (after receiving 10 Gy whole body irradiation, all the mice not intraperitoneally injected Rivastigmine died within 10 d; and for the mice intraperitoneally injected Rivastigmine, the survival rate of the mice was still greater than 40% 30 d later), and thus might have good radiation-proof effect.

Abstract: The present invention relates to a silicone composition comprising the three silicone compounds: stearyl dimethicone, a C30-45 alkyl methicone, and a caprylyl methicone. Said combination provides a unique effect in the treatment of scars, by increasing hydration of stratum corneum and thereby facilitates regulation of fibroblast production and reduction in collagen production, whereby treatment of skin injuries is obtained. Said composition can be applied as a thin transparent silicone film on a desired skin area, does not require any drying time, and has an improved adherence to the patient's skin, thereby improving patient compliance during treatment. Furthermore, said silicone composition can be provided with an SPF of 50 and a relatively high silicone concentration.